Paper36095166
The Tumor Microenvironment of Clear-Cell Ovarian Cancer.
Devlin MJ and 9 others. Cancer Immunol Res, 2022. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. The Tumor Microenvironment of Clear-Cell Ovarian Cancer. Papers, record 36095166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36095166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Ovarian Neoplasms | Major topic |
| Female | |
| Humans | |
| Programmed Cell Death 1 Receptor | |
| CD8-Positive T-Lymphocytes | |
| Collagen |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| C16420/A18066 | Cancer Research UK | United Kingdom | PubMed | |
| C355/A25137 | Cancer Research UK | United Kingdom | PubMed | |
| MR/S00629×1 | Medical Research Council | United Kingdom | PubMed | |
| MR/S00629X/1 | Medical Research Council | United Kingdom | PubMed | |
| A16354 | Cancer Research UK | United Kingdom | PubMed | |
| A25714 | Cancer Research UK | United Kingdom | PubMed | |
| 25714 | Cancer Research UK | United Kingdom | PubMed | |
| G-MGU0418 | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33504622 | A FIJI macro for quantifying pattern in extracellular matrix. | Life Sci Alliance | 2021 | https://conductscience.org/library/papers/33504622 | PubMed |
| 2 | 25428504 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. | Nature | 2014 | https://conductscience.org/library/papers/25428504 | PubMed |
| 3 | 27475412 | Immune-inflammation gene signatures in endometriosis patients. | Fertil Steril | 2016 | https://conductscience.org/library/papers/27475412 | PubMed |
| 4 | 17007852 | Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. | Fertil Steril | 2006 | https://conductscience.org/library/papers/17007852 | PubMed |
| 5 | 31311810 | HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. | Cancer Res | 2019 | https://conductscience.org/library/papers/31311810 | PubMed |
| 6 | 30410077 | TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. | Nat Commun | 2018 | https://conductscience.org/library/papers/30410077 | PubMed |
| 7 | 28266140 | Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. | Cancer Sci | 2017 | https://conductscience.org/library/papers/28266140 | PubMed |
| 8 | 28796747 | Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma. | Int J Gynecol Pathol | 2018 | https://conductscience.org/library/papers/28796747 | PubMed |
| 9 | 20942669 | ARID1A mutations in endometriosis-associated ovarian carcinomas. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20942669 | PubMed |
| 10 | 31046082 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31046082 | PubMed |
| 11 | 27536203 | The association between interleukin-4 -590C/T genetic polymorphism, IL-4 serum level, and advanced endometriosis. | Cent Eur J Immunol | 2016 | https://conductscience.org/library/papers/27536203 | PubMed |
| 12 | 31519915 | B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. | Nat Commun | 2019 | https://conductscience.org/library/papers/31519915 | PubMed |
| 13 | 22159717 | The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. | Mol Cell Proteomics | 2012 | https://conductscience.org/library/papers/22159717 | PubMed |
| 14 | 19892717 | Role of TGF-betas in normal human endometrium and endometriosis. | Hum Reprod | 2010 | https://conductscience.org/library/papers/19892717 | PubMed |
| 15 | 26087191 | COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. | Oncotarget | 2015 | https://conductscience.org/library/papers/26087191 | PubMed |
| 16 | 31339433 | Interactions between TGF-β type I receptor and hypoxia-inducible factor-α mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. | Cell Cycle | 2019 | https://conductscience.org/library/papers/31339433 | PubMed |
| 17 | 29575153 | Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. | Histopathology | 2018 | https://conductscience.org/library/papers/29575153 | PubMed |
| 18 | 16642009 | GenePattern 2.0. | Nat Genet | 2006 | https://conductscience.org/library/papers/16642009 | PubMed |
| 19 | 31869309 | IL-2 and IL-27 synergistically promote growth and invasion of endometriotic stromal cells by maintaining the balance of IFN-γ and IL-10 in endometriosis. | Reproduction | 2020 | https://conductscience.org/library/papers/31869309 | PubMed |
| 20 | 17640886 | Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17640886 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984928 | Immunotherapy in Advanced Epithelial Ovarian Cancer: Successes and Frustrations. | Oncol Res | 2026 | https://conductscience.org/library/papers/42984928 | PubMed |
| 42721374 | Profiling tumor immune microenvironment of epithelial ovarian carcinoma. | Oncoimmunology | 2026 | https://conductscience.org/library/papers/42721374 | PubMed |
| 42420312 | Spatial transcriptomic profiling of ovarian clear cell carcinoma reveals heterogeneity in OXPHOS and EMT gradients. | Nat Commun | 2026 | https://conductscience.org/library/papers/42420312 | PubMed |
| 42129168 | Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/42129168 | PubMed |
| 41994332 | Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer. | iScience | 2026 | https://conductscience.org/library/papers/41994332 | PubMed |
| 41969482 | Analysis of prognostic factors in ovarian clear cell carcinoma: a retrospective cohort study. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41969482 | PubMed |
| 41883867 | Molecular profile and targeted therapies for ovarian clear cell ovarian cancer. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/41883867 | PubMed |
| 41723536 | Distinct immune microenvironments in ovarian cancer subtypes indicate potential for immunotherapies. | J Transl Med | 2026 | https://conductscience.org/library/papers/41723536 | PubMed |
| 41634757 | Role of immune cells in clear cell ovarian cancer: a two-sample bidirectional Mendelian randomization study. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/41634757 | PubMed |
| 41383608 | The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective. | Front Immunol | 2025 | https://conductscience.org/library/papers/41383608 | PubMed |
| 41020848 | Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41020848 | PubMed |
| 40948537 | Enhanced prognostic stratification in early-stage epithelial ovarian cancer: multi-histological analysis of neutrophil-to-lymphocyte ratio with particular emphasis on clear cell histology. | Am J Cancer Res | 2025 | https://conductscience.org/library/papers/40948537 | PubMed |
| 40705396 | Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40705396 | PubMed |
| 40382714 | Effectiveness and safety of pembrolizumab for the treatment of Japanese patients with microsatellite instability-high tumors excluding colorectal cancer: a post-marketing surveillance. | Jpn J Clin Oncol | 2025 | https://conductscience.org/library/papers/40382714 | PubMed |
| 39608974 | Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/39608974 | PubMed |
| 38929687 | Genetic Links between Endometriosis and Endometriosis-Associated Ovarian Cancer-A Narrative Review (Endometriosis-Associated Cancer). | Life (Basel) | 2024 | https://conductscience.org/library/papers/38929687 | PubMed |
| 38886573 | The importance of 3D fibre architecture in cancer and implications for biomaterial model design. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/38886573 | PubMed |
| 38847966 | Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38847966 | PubMed |
| 38492450 | Targeting the immune microenvironment in ovarian cancer therapy-mission impossible? | ESMO Open | 2024 | https://conductscience.org/library/papers/38492450 | PubMed |
| 38410204 | Developing and validating the model of tumor-infiltrating immune cell to predict survival in patients receiving radiation therapy for head and neck squamous cell carcinoma. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/38410204 | PubMed |
Genes30
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36095166
GET https://conductscience.org/api/papers/v1/36095166/references?page=2